Brief: Heron Therapeutics Announces Preliminary, Unaudited Q4 Results
09/01/2026 14:37
Jan 9 (Reuters) - Heron Therapeutics Inc HRTX.O: HERON THERAPEUTICS ANNOUNCES PRELIMINARY, UNAUDITED Q4 AND FULL-YEAR 2025 NET REVENUE; ZYNRELEF® LARGEST CONTRIBUTOR TO Q4 GROWTH HERON THERAPEUTICS INC - REPORTS Q4 2025 NET REVENUE OF $40.5 MILLION Source text: ID:nGNX1r0qCG Further company coverage: HRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop